Japan Chemical Research Co., Ltd.

Toyohiko Nishimura

Hajime Hiratani

Naomi Uchida

Yoshikazu Yuki

A tumor cytostatic-cytocidal factor is produced by disrupting platelets, extracting the disrupted platelets with an acidic aqueous solution or an acidic water-organic solvent mixture, and, after gel filtration, if desired, to separate a fraction having an estimated molecular weight of 10,000 to 20,000 and having tumor cell growth inhibiting activity, subjecting said extract or said fraction to chromatography to isolate a cytostatic fraction having a molecular weight of 10,000 to 20,000 and an isoelectric point of 9.0 to 10.0, giving a positive nihidrin reaction and being such that it is deactivated by trypsin but not deactivated by heating in physiological saline solution at 60.degree. C. for 30 minutes or contacting at room temperature with 0.2N hydrochloric acid for 60 minutes or 70% formic acid for 30 minutes.

Tumor cytostatic-citocidal factor from blood platelets

Crude HCG is purified by extracting with a neutral or weakly basic aqueous solution containing lower aliphatic alcohol and soluble salt, adding lower aliphatic alcohol to the extracted solution to form precipitates and the precipitates containing high purity of HCG are collected. This precipitates can be further purified by dissolving in a buffer solution, contacting the solution with a weak anion exchanger and eluting the exchanger with said buffer solution containing added salt.

Process for producing highly purified HCG

A method for producing a human epidermal growth factor in high yield and high purity by adding particles of an aluminum or magnesium silicate of the formula z.2 (or 6) SiO.sub.2.xH.sub.2 O where Z is Al.sub.2 O.sub.3 or 2MgO and x is the number of water molecules in each molecule of the compound, to human urine under neutral to acid conditions to adsorb the factor on the particles and then eluting the factor with an alkaline solution.

Method of producing human epidermal growth factor

Gastric acid secretion inhibiting substance obtainable from mammalian urine by conventional method is fractionated into the first and second components by gel filtration, adsorption and desorption on ion exchanger or electrophoresis detecting each component by biological test methods. The activities of the two components differ from each other in the biological tests. The first component is a glucoprotein-like substance of M.W. 100,000 and the second component is a peptide-like substance of M.W. about 6,000.

Growing community of inventors

Ashiya, Japan

Toyohiko Nishimura